Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day
REDWOOD CITY, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the management team will participate in BTIG’s 3rd Annual Ophthalmology Day, taking place virtually on November 27th.
The Rezolute team is scheduled to participate in a question and answer session on November 27th at 11:30 am PT / 2:30 pm ET, including a discussion of RZ402, its oral plasma kallikrein inhibitor for diabetic macular edema. The Company will also hold investor meetings over the course of the conference day.
About Rezolute, Inc.